Prednisone pulse therapy for refractory myeloma.

Area of Science:

• Oncology
• Hematology
• Clinical Pharmacology

Background:

• Refractory multiple myeloma presents a significant clinical challenge.
• Limited treatment options exist for patients with advanced and resistant disease.

Purpose of the Study:

• To evaluate the efficacy of vindesine and a frequent prednisone schedule in refractory myeloma.
• To determine optimal combination chemotherapy regimens for improved patient outcomes.

Main Methods:

• A study involving 70 patients with refractory myeloma.
• Assessment of vindesine monotherapy, intermittent high-dose prednisone (alone or with vindesine), and combination therapy (prednisone pulses, vincristine, doxorubicin).

Main Results:

• Vindesine monotherapy yielded no patient response.
• Approximately 25% of patients showed tumor reduction with intermittent high-dose prednisone.
• A 47% response rate was observed with the combination of prednisone pulses, vincristine, and doxorubicin.
• Responding patients achieved excellent remission quality and significantly prolonged survival.

Conclusions:

• Frequent corticosteroid schedules, particularly high-dose prednisone, are beneficial in refractory myeloma.
• Combination chemotherapy including doxorubicin and prednisone pulses offers superior outcomes in advanced resistant multiple myeloma.
• Increased doxorubicin dosage may enhance treatment efficacy in this patient population.